SPI-256: Phase I data

In a double-blind, placebo-controlled Phase I trial in 59 healthy volunteers, SPI-256 was well-tolerated over a dose range of 150, 450, 600, 900 or 1,200 mg and over a dose range of 150, 450 or 900 mg...